Cargando…
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
BACKGROUND: Tumor resistance to the selective estrogen receptor modulator tamoxifen remains a serious clinical problem especially in patients with tumors that also overexpress HER2. We have recently demonstrated that the clinically important isoform of HER2, HERΔ16, promotes therapeutically refracto...
Autores principales: | Cittelly, Diana M, Das, Partha M, Spoelstra, Nicole S, Edgerton, Susan M, Richer, Jennifer K, Thor, Ann D, Jones, Frank E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024251/ https://www.ncbi.nlm.nih.gov/pubmed/21172025 http://dx.doi.org/10.1186/1476-4598-9-317 |
Ejemplares similares
-
miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer
por: HE, YUE-JUN, et al.
Publicado: (2013) -
Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a
por: Finlay-Schultz, Jessica, et al.
Publicado: (2014) -
Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors
por: Cittelly, Diana M., et al.
Publicado: (2010) -
miR-200c Targets a NF-κB Up-Regulated TrkB/NTF3 Autocrine Signaling Loop to Enhance Anoikis Sensitivity in Triple Negative Breast Cancer
por: Howe, Erin N., et al.
Publicado: (2012) -
Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive
Cancers
por: Cochrane, Dawn R., et al.
Publicado: (2010)